Premium
Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM‐M)
Author(s) -
Zakem Michael H.,
Davis Bryan R.,
Adelstein David J.,
Hines John D.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861215)58:12<2611::aid-cncr2820581210>3.0.co;2-w
Subject(s) - mycosis fungoides , medicine , bleomycin , nitrogen mustard , methotrexate , stage (stratigraphy) , chemotherapy , splenectomy , surgery , vincristine , doxorubicin , lymphoma , dermatology , gastroenterology , cyclophosphamide , spleen , paleontology , biology
Ten patients with advanced stage (TNM IIB‐IVB) mycosis fungoides were treated with a combination chemotherapy program consisting of bleomycin and methotrexate weekly, doxorubicin every 3 weeks, and topical nitrogen mustard daily (BAM‐M). Seven patients obtained histologically documented complete remissions ranging from 4 to 105+ months in duration. Median survival is 16.5+ months. Three patients in whom splenomegaly was detected during their staging evaluation underwent splenectomy. These three patients have had unmaintained disease‐free survivals of 36+, 100+, and 105+ months. This study indicates that BAM‐M is effective therapy for advanced stage mycosis fungoides and suggests that the therapeutic role of splenectomy should be evaluated further.